BOVN.F logo

BioInvent International OTCPK:BOVN.F Stock Report

Last Price

US$4.70

Market Cap

US$249.2m

7D

0%

1Y

n/a

Updated

26 Oct, 2022

Data

Company Financials +

BioInvent International AB (publ)

OTCPK:BOVN.F Stock Report

Market Cap: US$249.2m

BOVN.F Stock Overview

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.

BOVN.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BioInvent International AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioInvent International
Historical stock prices
Current Share Pricekr4.70
52 Week Highkr6.63
52 Week Lowkr2.98
Beta0.48
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO1.08%

Recent News & Updates

Recent updates

Shareholder Returns

BOVN.FUS BiotechsUS Market
7D0%0.2%1.3%
1Yn/a10.2%29.8%

Return vs Industry: Insufficient data to determine how BOVN.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how BOVN.F performed against the US Market.

Price Volatility

Is BOVN.F's price volatile compared to industry and market?
BOVN.F volatility
BOVN.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BOVN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BOVN.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199689Martin Welschofhttps://www.bioinvent.com

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.

BioInvent International AB (publ) Fundamentals Summary

How do BioInvent International's earnings and revenue compare to its market cap?
BOVN.F fundamental statistics
Market capUS$249.15m
Earnings (TTM)-US$3.84m
Revenue (TTM)US$27.21m

9.2x

P/S Ratio

-64.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOVN.F income statement (TTM)
Revenuekr295.46m
Cost of Revenuekr0
Gross Profitkr295.46m
Other Expenseskr337.13m
Earnings-kr41.66m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 27, 2022

Earnings per share (EPS)-0.64
Gross Margin100.00%
Net Profit Margin-14.10%
Debt/Equity Ratio0%

How did BOVN.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.